| Document |
Document Title |
|
WO/2022/021508A1 |
A method and a system for using a pulsed laser to control drug release, relating to the technical field of pulsed laser applications. A solution (6) used in the invention comprises an agarose hydrogel (8) carrier, an anti-cancer drug (9)...
|
|
WO/2022/019304A1 |
The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of t...
|
|
WO/2022/018198A1 |
The present invention relates to the treatment of viral infections using photosensitizers. More particularly, the present invention provides treatments for infections by viruses infecting the respiratory tract of a subject, in particular...
|
|
WO/2022/015986A1 |
The present technology relates generally to methods for treating, preventing, and/or ameliorating metastasis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of low dose carbon monox...
|
|
WO/2022/015823A2 |
Disclosed are methods for screening for therapeutic agents that can inhibit a coronavirus infection and methods of using agents identified by said assays to treat a coronavirus infection.
|
|
WO/2022/007298A1 |
Disclosed are a composite nanosphere having fast mucus penetration, a preparation method therefor and use thereof. Specifically disclosed is a composite nanosphere comprising a metal organic framework ZIF-8 and a hydrophilic macromolecul...
|
|
WO/2022/008703A1 |
The invention concerns a dye for use in a method of photoporation of the inner limiting membrane (ILM) of an eye in a subject. Preferably, the method comprises: administering the dye to the vitreous chamber of the eye of the subject; and...
|
|
WO/2022/008704A1 |
The invention concerns a dye for use in a method of treating a vitreous opacity-related disease in a subject. The method preferably comprises administering the dye to the vitreous body of an affected eye of the subject; and irradiating a...
|
|
WO/2022/011305A2 |
Infection by SARS-CoV-2 is impacting human subjects in their respiratory system and in some cases, their central nervous system (CNS). The virus is hurting certain groups of people more than others, such as the elderly and those with oth...
|
|
WO/2022/009788A1 |
The killing method according to the present invention comprises: a step for emitting X-rays to a scintillator to generate ultraviolet rays from the scintillator; and a step for causing the generated ultraviolet rays to reach target cells...
|
|
WO/2022/006232A2 |
Methods of screening drugs and compounds, potentially useful in treating SARS-CoV-2, which have been approved previously by the U.S. Food and Drug Administration for other purposes, are provided. In particular, a computational protein st...
|
|
WO/2022/001255A1 |
The present invention relates to the field of biomedicine, and specifically relates to a contrast agent film-forming agent composition, a contrast agent film-forming lipid solution containing the contrast agent film-forming agent composi...
|
|
WO/2022/001253A1 |
A magnetic ultrasound contrast agent composition, a magnetic ultrasound contrast agent, and a magnetic microbubble ultrasound contrast agent and a preparation method therefor. The magnetic ultrasound contrast agent composition comprises ...
|
|
WO/2022/003293A1 |
The present invention relates to a self-assembled structure for use in the treatment of mammalian cancer, the structure being between 50 and 1,500 nm in size and comprising a plurality of nanocrystals chosen from metal or metal oxide nan...
|
|
WO/2022/006133A2 |
Provided herein are agents that modulate histone acetylation and pathways downstream thereof, and methods for the treatment and prevention of organ injury therewith. In particular, provided herein are combinations of histone deacetylase ...
|
|
WO/2021/262562A2 |
Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a HIF-2α inhibitor; and (c) lenvatinib, or a pharmaceut...
|
|
WO/2021/259423A1 |
The invention relates to the use of at least one inhibitory structural analog or inhibitory functional analog of a coenzyme (such as thiamine for example) of an enzyme group, the enzyme members of which catalyze anabolic and/or catabolic...
|
|
WO/2021/257314A1 |
A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluoresc...
|
|
WO/2021/255440A1 |
The present invention provides a core-shell micro-particle comprising a biodegradable polymer with at least two or more surface cavities. The present invention also provides use of the core-shell micro-particle in drug delivery, contrast...
|
|
WO/2021/255441A1 |
The present invention provides a core-shell microparticle comprising a biodegradable polymer with at least two or more surface cavities for use in the treatment of vascular disease, wherein the shell further comprises one or more drugs. ...
|
|
WO/2021/252685A1 |
An ultraviolet irradiation (UBI) device is configured to simultaneously irradiate blood flowing through a flat quartz crystal cuvette with both UV-A and UV-C light, wherein UV-A and UV-C lamps are positioned on opposite sides of the cuve...
|
|
WO/2021/252709A1 |
The disclosure relates in one aspect to methods of treating, ameliorating, and/or preventing certain S1R and/or S2R-related diseases and/or disorders, such as for example certain viral infections in a subject, comprising administering to...
|
|
WO/2021/252896A2 |
Described herein are methods and compositions for treating a coronavirus infectious disease, e.g., COVID-19. Aspects of the invention relate to administering to a subject an agent that targets Notch4.
|
|
WO/2021/252511A1 |
A luminaire includes a housing configured to he positioned over an area, the housing including a frame having a first channel for receiving a light emitter. A light emitter is positioned in the first channel. The light emitter is configu...
|
|
WO/2021/248674A1 |
An antibacterial nanozyme and a preparation method therefor, relating to the technical field of antibacterial material. The preparation method is as follows: 1) heating and stirring an aqueous chloroauric acid solution, adding an aqueous...
|
|
WO/2021/246757A1 |
The present invention relates to: a pharmaceutical composition which is for enhancing radiotherapy and comprises a fusion protein dimer containing IL-2 protein and CD80 protein; and a method for cancer radiotherapy using same. The compos...
|
|
WO/2021/248021A1 |
Provided are instrument treatment systems, the systems including an insertable portion, the insertable portion being configured for insertion into the bore of a medical imaging system, the insertable portion comprising at least one sourc...
|
|
WO/2021/239730A1 |
The present invention relates to the field of human health and advantageously offers therapeutic solutions to cancer patients up to now considered by multidisciplinary (oncology) teams (considering guidelines standards) as unable to unde...
|
|
WO/2021/242630A1 |
Methods for inducing cell death by magneto-endosomalytic therapy using magnetic nanoparticles. The methods include inducing cell death, inducing cell death in a subject, and application of the methods to killing tumor cells in a subject.
|
|
WO/2021/242279A1 |
A general serum procedure for all of pathogens with protein coding on an outer shell of the pathogens, comprises entering dead pathogens and their dead genomes to eliminate pathogens and cancer genes in humans and animals. A device for d...
|
|
WO/2021/243007A2 |
Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-CoV-2 infection and related ...
|
|
WO/2021/237209A1 |
Modified metal-organic framework (MOFs) are described that have surfaces with enhanced ability to coordinatively bond to or electrostatically interact with therapeutic agents, such as nucleic acids and small molecules and proteins with p...
|
|
WO/2021/236985A1 |
Disclosed herein are methods for treating acute respiratory distress syndrome, lung injury, respiratory failure, and associated conditions using activators of Tie-2 and inhibitors of HPTPβ. The methods include reducing vascular leak and...
|
|
WO/2021/235661A1 |
The present invention relates to a fatty acid-biocompatible polymer-photosensitizer conjugate. The conjugate can kill GIP-secreting cells by generating active oxygen upon irradiation with light, and has the effect of increasing insulin, ...
|
|
WO/2021/229550A1 |
Hydroalcoholic composition based on physiological solution and/or distilled water and ethanol in a concentration by volume comprised between 0.3 per thousand and 5 per thousand, for internal or external use, for the reduction of the vira...
|
|
WO/2021/231639A1 |
This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a cancer therapy, e.g., radiation, an anthracycline, a folic acid analog, a platinum-based agent, a ta...
|
|
WO/2021/231327A2 |
Disclosed are treatments for cancer that enhance a patient immune systems' ability to detect and attack cancer. The present disclosure provides methods for treating cancer in a subject in need thereof comprising administering to the subj...
|
|
WO/2021/231762A2 |
Methods of treating patients diagnosed with or suspected of having triple negative breast cancer with a combination of compounds that target PI3K isoforms and target PTK7.
|
|
WO/2021/231499A2 |
Provided are methods of treating a mammal for a virus infection. The methods comprise (a) increasing ribonuclease amount or activity in a cell infected by the virus; (b) decreasing protein production in a cell infected by the virus; (c) ...
|
|
WO/2021/226849A1 |
The present disclosure relates to an immunologically active peptide-biliverdin conjugate (I), a preparation method therefor and an application thereof in cancer diagnosis, and/or tumor immunotherapy, and/or tumor "photothermal immunother...
|
|
WO/2021/231804A2 |
Disclosed herein are methods and compositions for treating or inhibiting disorders resulting from a C9orf72 mutation. In some embodiments, the methods and compositions comprise administering an agent that alters the gut microbiome of an ...
|
|
WO/2021/231908A2 |
The disclosure provides methods of enhancing susceptibility of neoplastic, transformed, and/or cancer cells ("cancer cells") to immunotherapeutic agents. The methods comprise contacting the cancer cell with an agent that modulates RNA sp...
|
|
WO/2021/232067A1 |
The subject invention pertains to the use of STATS inhibitors for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or ...
|
|
WO/2021/231795A1 |
Provided are methods and uses for treating a cancer or a tumor. In some aspects, the provided methods and uses involve contacting a sample, e.g., containing tumor cells, with a phthalocyanine dye conjugated to a targeting molecule that b...
|
|
WO/2021/231872A1 |
The present disclosure relates to a composition and method for enhancing a drug's efficacy by combining the drug with a mammalian protease inhibitor such as a cathepsin inhibitor. Methods for using the combination of the disclosure for t...
|
|
WO/2021/224687A1 |
Disclosed are methods and compositions for preventing or disrupting mitosis of pluripotent stem cells, killing pluripotent stem cells, preventing or disrupting division of pluripotent stem cells, reducing the viability of pluripotent ste...
|
|
WO/2021/224169A1 |
The present invention relates to a process for the irradiation of a water-insoluble conjugate comprising a polymer Z to which a plurality of moieties -L2-L1-D is covalently conjugated or of a water-insoluble complex comprising a pluralit...
|
|
WO/2021/221287A1 |
The present invention relates to gas precursor-containing nanoparticles (nanobubbles), an anticancer composition based thereon and a method for producing the nanobubbles, and relates to an ultrasound-mediated anticancer drug capable of i...
|
|
WO/2021/222903A2 |
A composition for treating abnormal or excessive angiogenesis, such as pyogenic granuloma comprising an anti-vascular endothelial growth factor (anti-VEGF) agent (e.g., an antibody or small molecule inhibitor of VEGF signaling) and a car...
|
|
WO/2021/221330A1 |
The present invention relates to a sonosensitive liposome and a method for preparing same, and the sonosensitive liposome, according to the present invention, increases the delivery efficiency of an encapsulated drug and, by being used i...
|
